Edoxaban (tosylate Monohydrate) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. Edoxaban (tosylate Monohydrate) was developed by Daiichi Sankyo and approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. Edoxaban (tosylate Monohydrate) was also approved by the FDA in January 2015 for the prevention of stroke and non-central-nervous-system systemic embolism.

Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor.
Eduxaban is a selective coagulation factor Xa inhibitor oral tablet that prevents and treats deep vein thrombosis and pulmonary embolism, and is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).